Cognitive Deficits in Depression
neuroscienceCME Multimedia SnackPremiere Date: Monday, May 8, 2017
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, May 8, 2018
Note: Credit Is No Longer Available
|Charles B. Nemeroff, MD, PhD
Professor and Chair
Department of Psychiatry
Mulva Clinic for the Neurosciences
Director, Institute of Early Life Adversity Research
Dell Medical School
The University of Texas at Austin
|Alan F. Schatzberg, MD
Kenneth T. Norris, Jr., Professor
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Depression is one of the biggest health challenges the world faces. More than 350 million people worldwide suffer from depression. Many patients with depression report cognitive difficulties and clinicians must be able to properly assess these difficulties when treating patients with MDD.
While cognitive dysfunction in MDD may improve with treatment and depressive symptoms may resolve, cognitive deficits can still be detected even in periods of symptom remission. The proportion of time with cognitive complaints was reported as 94% during acute depressive episodes; this remained at 44% despite full or partial symptom remission during treatment.1 Measurement-based assessment tools have helped to quantify the degree of depression; however, these tools continue to be underutilized in everyday practice.2
This NeuroscienceCME Snack features expert faculty offering new perspectives on treating this pervasive disorder and highlighting cognitive deficits as a challenge to clinicians.
1. Baune BT, Miller R, McAfoose J, et al. The role of cognitive impairment in general functioning in major depression. Psychiatry Res.2010;176(2-3):183-189.
2. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155-162.
At the end of this CE activity, participants should be able to:
- Improve the assessment of cognition in patients with major depression.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Physicians, pharmacists, and other health care professionals who manage patients with mood disorders.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs) Universal Activity Number:
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff has disclosed that he receives grants/research support from National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Fortress Biotech; Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); Xhale, Inc. He is a stockholder of AbbVie Inc.; Bracket; Celgene Corporation; Intermediate Holding Corp.; Network Life Sciences Inc.; OPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; Xhale, Inc. He has patents for Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). He serves on the scientific advisory boards of American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara); Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Laureate Institute for Brain Research, Inc. RiverMend Health, LLC; Skyland Trail; Xhale, Inc. He serves on the board of directors for American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc. He receives income sources or equity of $10,000 or more from American Psychiatric Publishing; Bracket (Clintara); Takeda Pharmaceuticals North America, Inc.; Xhale, Inc.
Dr. Schatzberg has disclosed that he receives grants from Janssen Pharmaceuticals. He serves as a consultant to Alkermes; Clintara; Forum Pharmaceuticals, Inc.; McKinsey & Company; and Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder (directly Purchased) for Corcept Therapeutics; Titan Pharmaceuticals, Inc.; Seattle Genetics, Inc.; Incyte Corporation; Gilead; and Merck & Co., Inc.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).